임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 1상모집 중단 (진행 중)· HealthyA Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· HyperlipidemiaA Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Arthritis, RheumatoidA Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Hidradenitis SuppurativaStudy to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Pulmonary Arterial HypertensionA Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Hypertension, PulmonaryExtension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Human Immunodeficiency Virus Type 1 (HIV-1) InfectionA Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Gastrointestinal CancerA Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Advanced Solid TumorA Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· HealthyA Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Melanoma MetastaticDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Breast CancerStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Classical Hodgkin Lymphoma RecurrentA Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· HIV-1-infectionStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· HIV-1-InfectionStudy to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MSI-H/dMMR Gastroesophageal-junction CancerA Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
협력: 머크(MSD)
- 1상모집 중단 (진행 중)· MelanomaA Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· HypercholesterolemiaOpen-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Lung CancerOncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Colorectal CancerPhase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Essential ThrombocythemiaBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Neoplasm MetastasisA Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Non-alcoholic Fatty Liver DiseaseA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Non-small Cell Lung Cancer (NSCLC)Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
리드: 머크(MSD)
- 2/3상모집 중단 (진행 중)· Head and Neck Squamous Cell CarcinomaStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Gastroesophageal CancerA Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Renal Cell CarcinomaA Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
리드: 머크(MSD) · 협력: 모더나
- 1/2상모집 중단 (진행 중)· Bladder CancerA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
리드: 머크(MSD) · 협력: 모더나
- 2상모집 중단 (진행 중)· Malignant Pleural MesotheliomaStudy of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Glioblastoma MultiformeT Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Stage IIIB(N2) Non-small Cell Lung CancerPembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Triple-Negative Breast CancerPhase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Hodgkin LymphomaPET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Endometrial CancerSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid TumorsBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Endometrial CancerNeo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Non-small Cell Lung Cancer (NSCLC)Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
리드: 머크(MSD)
- 1상모집 중단 (진행 중)· Non-small Cell Lung CancerSacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Ulcerative ColitisA Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
리드: 머크(MSD)
- 2상모집 중단 (진행 중)· Squamous Cell CarcinomaA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· ArteriosclerosisEnlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
리드: 머크(MSD)
- 3상모집 중단 (진행 중)· Kidney Transplant; ComplicationsDe-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Urothelial CarcinomaDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
리드: 화이자 · 협력: 머크(MSD)
- 2상모집 중단 (진행 중)· Metastatic Pancreatic Ductal AdenocarcinomaBXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
협력: 머크(MSD)
- 3상모집 중단 (진행 중)· MelanomaA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
리드: 머크(MSD) · 협력: 모더나
- 2상모집 중단 (진행 중)· Breast CancerA Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.